Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Redx Pharma Plc RNS Release

Redx to present new scientific data at ESMO 2017


RNS Number : 4130P
Redx Pharma plc
31 August 2017
 

31 August 2017

REDX PHARMA PLC (in administration)

("Redx" or "the Company")

 

Redx to present new scientific data at ESMO 2017

 

Redx Pharma will present a poster on their planned first-in-human clinical trial for RXC004 at the European Society for Medical Oncology (ESMO) Annual Meeting, September 8-12, 2017, in Madrid.

 

Session Date & Time

September 9, 2017, 13:15 AM -14:15 GMT+1h

Session Title

GASTROINTESTINAL TUMOURS, COLORECTAL

Presentation Title

Identification of an RNF43 mutated gastric cancer patient population with potential sensitivity to porcupine inhibitor RXC004 and development of a complimentary ctDNA liquid biopsy assay for patient screening

Session Location

Hall 8

Abstract #

692P

First author

Matilda Bingham

 

Abstract online

 

https://cslide.ctimeetingtech.com/library/esmo/browse/search/2iw4#2Bb5o02mE

 

 

Iain Ross, Chairman, commented:

 

'We're delighted to present new scientific data on our most advanced program, the Porcupine inhibitor RXC004 as it moves closer to the clinic. We have a strong portfolio of research assets and continue to look for novel opportunities in several therapeutic classes in oncology and immunology.'

 

 

For further information, please contact:

 

Redx Pharma Plc (in administration)


 

Contact for the Joint Administrators:

Chris French

James Rossiter

 

 

T: + 44 203 005 4000

 

Cantor Fitzgerald Europe (Nomad & Broker)

 

T: +44 20 7894 7000

Phil Davies




WG Partners LLP (Joint Broker)

T: +44 20 3705 9330

Claes Spång/ Chris Lee/ David Wilson




About Redx Pharma Plc (in administration)

 

Company website: redxpharma.com

 

Jason Baker and Miles Needham have been appointed as joint administrators of Redx Pharma plc (in administration). The company's affairs, business and property are being managed by the joint administrators.

 

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRASDWSWFFWSEIA



Redx Pharma Plc Timeline

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use